美国食品药品监督管理局对治疗慢性肾脏病贫血时血红蛋白快速上升风险的看法：何去何从。 - Suppr

Suppr

超能文献

The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.

作者信息

Singh Ajay K

出版信息

Clin J Am Soc Nephrol. 2010 Apr;5(4):553-6. doi: 10.2215/CJN.00490110. Epub 2010 Mar 4.

DOI:10.2215/CJN.00490110

PMID:20203166

Abstract

摘要

相似文献

The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.美国食品药品监督管理局对治疗慢性肾脏病贫血时血红蛋白快速上升风险的看法：何去何从。

Clin J Am Soc Nephrol. 2010 Apr;5(4):553-6. doi: 10.2215/CJN.00490110. Epub 2010 Mar 4.

Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.反对对所有患者一视同仁：来自美国食品药品监督管理局咨询委员会会议的教训。

J Am Soc Nephrol. 2011 Jan;22(1):1-2. doi: 10.1681/ASN.2010111133. Epub 2010 Dec 16.

Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.个体化决策——在贫血症争论中重振医患关系。

Clin J Am Soc Nephrol. 2010 Jul;5(7):1340-6. doi: 10.2215/CJN.02830310. Epub 2010 May 6.

Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.促红细胞生成素刺激剂与患者生活质量：个体化贫血治疗。

Clin J Am Soc Nephrol. 2012 Feb;7(2):354-7. doi: 10.2215/CJN.11961111. Epub 2012 Jan 19.

Does TREAT give the boot to ESAs in the treatment of CKD anemia?在慢性肾脏病贫血的治疗中，TREAT是否会淘汰促红细胞生成素类药物？

J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24.

The new FDA labeling for ESA--implications for patients and providers.新的 FDA 针对 ESA 的标签说明——对患者和提供者的影响。

Clin J Am Soc Nephrol. 2012 Feb;7(2):348-53. doi: 10.2215/CJN.09960911. Epub 2012 Jan 19.

Triumph and tragedy: anemia management in chronic kidney disease.胜利与悲剧：慢性肾脏病的贫血管理

Curr Opin Nephrol Hypertens. 2008 Nov;17(6):580-8. doi: 10.1097/MNH.0b013e32830c488d.

Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?编辑视角。慢性肾病贫血患者的血红蛋白目标值是否应该改变？

Am J Nephrol. 2010;31(6):565-6. doi: 10.1159/000313894. Epub 2010 May 21.

The CARI guidelines. Biochemical and haematological targets. Haemoglobin.CARI指南。生化和血液学指标。血红蛋白。

Nephrology (Carlton). 2008 Jul;13 Suppl 2:S44-56. doi: 10.1111/j.1440-1797.2008.00997.x.

Erythropoiesis-stimulating agents in cancer.癌症中的促红细胞生成素刺激剂

J Clin Oncol. 2008 Jun 20;26(18):3097-8; author reply 3098-100. doi: 10.1200/JCO.2008.16.0531.

引用本文的文献

Roxadustat for Treating Anemia in Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis: A Retrospective Study.罗沙司他治疗未接受透析的晚期慢性肾脏病患者贫血的回顾性研究。

Intern Med. 2025 May 1;64(9):1303-1314. doi: 10.2169/internalmedicine.3773-24. Epub 2024 Oct 17.

Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period.血液透析开始时血红蛋白水平低：透析早期贫血管理与死亡率的一项国际研究

Clin Kidney J. 2019 Jul 5;13(3):425-433. doi: 10.1093/ckj/sfz065. eCollection 2020 Jun.

A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.一项评估罗沙司他间歇口服给药治疗未接受透析的非透析慢性肾脏病且对红细胞生成刺激剂初治的日本贫血患者的 3 期、多中心、随机、双盲、开放性研究

Nephron. 2020;144(8):372-382. doi: 10.1159/000508100. Epub 2020 Jun 24.

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.罗沙司他治疗未透析的日本慢性肾脏病相关贫血患者的疗效：一项 2 期、随机、双盲、安慰剂对照试验。

Adv Ther. 2019 Jun;36(6):1438-1454. doi: 10.1007/s12325-019-00943-4. Epub 2019 Apr 5.

Impact of hemoglobin variability on cardiovascular mortality in maintenance hemodialysis patients.血红蛋白变异性对维持性血液透析患者心血管死亡率的影响。

Int Urol Nephrol. 2018 Sep;50(9):1703-1712. doi: 10.1007/s11255-018-1919-5. Epub 2018 Jul 4.

A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease.通过分离慢性肾脏病贫血中血红蛋白上升速率的影响，揭示了一条阈值轨迹。

Ther Adv Drug Saf. 2017 Oct;8(10):305-318. doi: 10.1177/2042098617716819. Epub 2017 Jul 12.

The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease.贫血的发展与 NKF/KDOQI 分期 3 期慢性肾脏病的不良预后相关。

BMC Nephrol. 2013 Jan 7;14:2. doi: 10.1186/1471-2369-14-2.

Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR.更高血红蛋白目标对血压和临床结局的影响：CHOIR 的二次分析。

Nephrol Dial Transplant. 2012 Sep;27(9):3606-14. doi: 10.1093/ndt/gfs123. Epub 2012 May 9.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.化疗引起的贫血的癌症患者在基线血红蛋白水平<9 g/dL 时起始使用达贝泊汀α治疗与 9 至<10 g/dL 时起始治疗与≥10 g/dL 时起始治疗的输血风险：一项 3 期试验的探索性分析。

Med Oncol. 2012 Sep;29(3):2291-9. doi: 10.1007/s12032-011-0103-x. Epub 2011 Nov 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验